JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weinshenker, D.
Right arrow Articles by Palmiter, R. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weinshenker, D.
Right arrow Articles by Palmiter, R. D.

Vol. 298, Issue 3, 1042-1048, September 2001


alpha 1 and beta 2 Adrenoreceptor Agonists Inhibit Pentylenetetrazole-Induced Seizures in Mice Lacking Norepinephrine

David Weinshenker , Patricia Szot , Nicole S. Miller and Richard D. Palmiter

Howard Hughes Medical Institute (D.W., N.S.M., R.D.P.) and Departments of Biochemistry (D.W.) and Psychiatry and Behavioral Sciences (P.S.), University of Washington, Seattle, Washington; and Geriatric Research, Education, Clinical Center (GRECC), Puget Sound Health Care System, Seattle, Washington (P.S.)

    Abstract
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
Conclusions
References

It has been known for many years that norepinephrine (NE) is a potent endogenous anticonvulsant, yet there is confusion as to which receptor(s) mediate this effect. This is probably due to multiple factors, including the importance of distinct signaling pathways for different seizure paradigms, a lack of comprehensive pharmacological studies, and difficulty in interpreting existing pharmacological results due to the presence of endogenous NE. We sought to circumvent these problems by testing the anticonvulsant activity of selective agonists for most known adrenoreceptors (ARs) in dopamine beta -hydroxylase knockout (Dbh -/-) mice that lack endogenous NE. Dbh -/- mice are hypersensitive to pentylenetetrazole (PTZ)-induced seizures, demonstrating that endogenous NE inhibits PTZ-induced seizures in the wild type. Pretreatment of Dbh -/- mice with an alpha 1AR or beta 2AR, but not an alpha 2AR or beta 1AR agonist significantly protected against PTZ-induced seizures. In contrast, only the beta 2AR agonist showed anticonvulsant activity in heterozygous controls. Furthermore, an alpha 1AR antagonist exacerbated PTZ-induced seizures in control mice, whereas a beta 2AR antagonist had no effect. We conclude that activation of the alpha 1AR is primarily responsible for the anticonvulsant activity of endogenous NE in the murine PTZ model of epilepsy. Endogenous NE probably does not activate the beta 2AR under these conditions, but exogenous activation of the beta 2AR produces an anticonvulsant effect.

    Introduction
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
Conclusions
References

The importance of endogenous norepinephrine (NE) as an anticonvulsant neurotransmitter is well established. For example, specific lesions of the central noradrenergic system using 6-hydroxydopamine (Corcoran et al., 1974) or N-(2-chloroethyl)-N-2-bromobenzylamine (Carre and Harley, 1986) result in increased seizure sensitivity. Conversely, stimulation of the locus coeruleus, the primary central noradrenergic nucleus, significantly inhibits seizures (Weiss et al., 1990). More recently, antiepileptic therapies used clinically have been shown to either increase central NE content or require an intact noradrenergic system for their efficacy (Waller and Buterbaugh, 1985; Baf et al., 1994; Krahl et al., 1998; P. Szot, D. Weinshenker, J. M. Rho, T. W. Storey, and P. A. Schwartzkroin, unpublished data). Despite the long-standing interest and experimentation along these lines, it is still unclear exactly how NE inhibits seizure activity. There are three primary reasons for this confusion.

First, the noradrenergic signaling system is extremely complex; three distinct classes of receptor with multiple subtypes have been cloned, and each class activates different G proteins. The alpha 1 class of adrenoreceptors (ARs) is linked to Go/Gq and activates phospholipase C and intracellular Ca2+ release. alpha 2ARs are linked to Gi and inhibit adenylate cyclase. beta ARs (beta 1AR and beta 2AR) are linked to Gs and activate adenylate cyclase (for review, see Cooper et al., 1996). All of these receptor classes are widely distributed throughout the brain and are found in regions implicated in regulating seizures such as the hippocampus, cortex, and amygdala. Differences in receptor distribution between animal species, strain, and the brain region(s) affected by seizure-inducing paradigms probably contribute to the variety of ARs shown to possess anticonvulsant activity (Papanicolaou et al., 1982; Lints and Nyquist-Battie, 1985; Neuman, 1986; Löscher and Czuczwar, 1987; Ferraro et al., 1994; Yan et al., 1998). Second, despite this complexity, many seizure susceptibility studies have not been pharmacologically comprehensive for any given seizure paradigm. For example, data have been presented exclusively on nonselective beta AR antagonists (Lints and Nyquist-Battie, 1985), nonselective beta AR agonists and antagonists (Ferraro et al., 1994), and alpha AR agonists and antagonists (Löscher and Czuczwar, 1987; Tsuda et al., 1990). In only a few studies have compounds that target both alpha ARs and beta ARs been tested (Neuman, 1986; Gellman et al., 1987; Micheletti et al., 1987), and even these were somewhat limited in their scope.

Third, although the alpha 2AR receptor is probably the most promiscuous anticonvulsant receptor in terms of efficacy across species, strain, and seizure paradigm (Papanicolaou et al., 1982; Baran et al., 1985; Scotti de Carolis et al., 1986; Löscher and Czuczwar, 1987; Jackson et al., 1991), proconvulsant effects have also been reported (Oishi et al., 1979; Löscher and Czuczwar, 1987; Wu et al., 1987). In addition, there are inherent difficulties interpreting any of these results. Three different subtypes of alpha 2AR exist (alpha 2A, alpha 2B, and alpha 2C) and they are localized both pre- and postsynaptically. Activation of presynaptic alpha 2AR autoreceptors decreases noradrenergic firing and NE release (L'Heureux et al., 1986; Jorm and Stamford, 1993), while activation of postsynaptic alpha 2ARs mimics the effect of released NE on target cells expressing these receptors and inhibits their firing (Gobert et al., 1998). Because available alpha 2AR agonists cannot distinguish between alpha 2AR subtypes or pre- versus postsynaptic alpha 2ARs, it is nearly impossible to interpret the effect of alpha 2AR agonists. In addition, there is some evidence that activation of presynaptic beta ARs facilitate central NE release (Murugaiah and O'Donnell (1995).

To address these issues, we have tested the effects of subtype-selective agonists and antagonists for most known ARs on susceptibility to pentylenetetrazole (PTZ)-induced seizures in dopamine beta -hydroxylase knockout (Dbh -/-) mice that are deficient in NE synthesis and lack NE, thereby isolating the postsynaptic effects of these compounds and eliminating any influence on NE release. Dbh -/- mice have increased susceptibility to PTZ-induced seizures, demonstrating that endogenous NE is anticonvulsant in this model of epilepsy (Szot et al., 1999). Both anticonvulsant (Löscher and Czuczwar, 1987; Amabeoku et al., 1994) and proconvulsant (Oishi et al., 1979; Fletcher and Forster, 1988) effects of clonidine on PTZ-induced seizures in mice have been reported. We predicted that the effects of clonidine would be abolished in Dbh -/- mice if it acts via presynaptic alpha 2ARs, but Dbh -/- mice would still be affected if the postsynaptic alpha 2ARs are involved.

    Materials and Methods
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
Conclusions
References

Animals. Dbh knockout (Dbh -/-) mice, maintained on a 129/SvEv and C57BL/6J hybrid background, were developed and generated as described (Thomas et al., 1998). Mice were reared in a specific pathogen-free facility with a 12-h light/dark cycle at the University of Washington (Seattle, WA), but moved to a conventional facility for seizure experiments. Mice between 3 and 6 months of age were used for all experiments, and food and water were available ad libitum.

Dbh -/- mice were identified by the delayed growth and ptosis phenotype, which is 100% correlated with the Dbh -/- genotype (data not shown). A subset of genotypes was confirmed by polymerase chain reaction. Dbh +/- mice have normal levels of epinephrine and NE and are indistinguishable from wild-type littermates for all previously tested behaviors, including seizure susceptibility (Thomas et al., 1998; Szot et al., 1999). Therefore, heterozygous (Dbh +/-) littermates were used as controls for all experiments in this study. Experimental protocols were approved by the animal care committee at the University of Washington and meet the guidelines of the American Association for Accreditation of Laboratory Animal Care.

Seizure Induction. Seizures were induced with an i.p. injection of PTZ dissolved in water. Because Dbh -/- mice are more sensitive to PTZ-induced seizures (Fig. 1; Szot et al., 1999), doses of PTZ were adjusted based on genotype in many experiments to elicit seizures of similar severity in Dbh +/- and Dbh -/- mice. PTZ was administered at a dose of 25, 30, or 40 mg/kg (6.25, 7.5, or 10 mg/ml) for Dbh -/- mice and 40 or 50 mg/kg (10 or 12.5 mg/ml) for Dbh +/- mice in a volume of 4 ml/kg. The lower doses of PTZ for each genotype, which produced mild seizures, were used when testing a drug that had a proconvulsant effect based on pilot experiments, while the higher doses produced severe seizures and were used when testing anticonvulsant compounds. Mice were placed in a clear Plexiglas chamber and closely observed for 10 min. This observation time was chosen because mice that displayed seizure activity did so within the first few minutes after PTZ administration and were typically postictal by 10 min. Latency to first myoclonic jerk (MJ) and clonic/tonic (C/T) seizure was recorded. Animals that did not experience one of these behavioral seizure landmarks were assigned a latency of 600 s for that measurement.


View larger version (12K):
[in this window]
[in a new window]
 
Fig. 1.   Susceptibility of Dbh +/- and Dbh -/- mice to PTZ-induced seizures. Shown are latencies to first MJ and C/T seizure. These data are a compilation of results with water and vehicle-injected mice followed by administration of 40 mg/kg PTZ from Figs. 2 through 4 (Dbh +/-, n = 49; Dbh -/-, n = 67). ****P < 0.0001 compared with Dbh +/-.

To test the effects of AR agonists and antagonists, clonidine, yohimbine, phenylephrine, cirazoline, isoproterenol, dobutamine, albuterol, prazosin, propanolol, ICI-118,551, or idazoxan (Sigma, St. Louis, MO) were administered intraperitoneally in a volume of 4 ml/kg 30 min prior to seizure induction with PTZ. To test the ability of an antagonist to block the anticonvulsant activity of an agonist, the antagonist was administered 30 min prior to the agonist. All drugs were dissolved in water with the exception of prazosin, which was dissolved in a mixture of 1.5% DMSO and 1.5% Cremaphor EL (Sigma). For prazosin experiments, the DMSO/Cremaphor EL solution was used as a vehicle control. Water was used as a vehicle control for all other experiments. Drug doses were based on those used in the murine seizure literature when available, and on published rat data or pilot experiments when a compound had not been previously test in mice.

Data were analyzed using Student's t tests for comparing two groups with means of equivalent variance, Mann-Whitney U tests for comparing two groups with means of nonequivalent variance, and analysis of variance followed by Newman-Keuls post hoc tests for comparing means from more than two groups. P < 0.05 was considered significant.

    Results
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
Conclusions
References

Dbh -/- Mice Are Hypersensitive to PTZ-Induced Seizures. We previously reported that Dbh -/- mice have shorter latencies to first MJ and C/T seizure than Dbh +/- mice following PTZ administration (Szot et al., 1999). We repeated this experiment with a larger number of mice and obtained the same result (Fig. 1), demonstrating that a lack of endogenous NE results in increased sensitivity to PTZ-induced seizures.

alpha 2AR Agonists Act via Autoreceptors to Exacerbate PTZ-Induced Seizures. To determine whether alpha 2AR agonists increased or decreased sensitivity to PTZ-induced seizures, we treated Dbh +/- mice with the alpha 2AR agonist clonidine prior to PTZ administration. Clonidine (0.1 mg/kg) had a proconvulsant effect that was most pronounced for latency to MJ (Fig. 2A). To determine whether this proconvulsant effect was mediated by an inhibition of NE release via presynaptic autoreceptors or via actions on postsynaptic heteroreceptors, we tested the effect of clonidine on PTZ-induced seizures in Dbh -/- mice. Clonidine did not alter seizure latency in Dbh -/- mice in response to 30 mg/kg PTZ (Fig. 2A) or 25 mg/kg PTZ (latency to MJ: vehicle = 317 ± 73 s, 0.1 mg/kg clonidine = 265 ± 29 s, P = 0.85; no C/T seizures observed), suggesting that the proconvulsant effect seen in control mice resulted from decreased NE release mediated by activation of presynaptic alpha 2AR autoreceptors. Clonidine treatment caused piloerection in both genotypes and rescued the bilateral ptosis phenotype of Dbh -/- mice, demonstrating that the drug possessed biological activity at this dose in the knockouts (data not shown). Blockade of alpha 2ARs with yohimbine (10 mg/kg) slightly increased seizure latency in both genotypes, but the effect was not significant (Fig. 2B). The weak anticonvulsant effect of yohimbine may have been nonspecific and caused by the significant sedation observed with this treatment. The alpha 2AR antagonist idazoxan (3 mg/kg), which lacks the sedative effects of yohimbine, also did not have a significant effect (data not shown). These results suggest that while exogenous activation of alpha 2ARs can exacerbate PTZ-induced seizures, activation of alpha 2ARs by endogenous NE is not involved under these conditions.


View larger version (44K):
[in this window]
[in a new window]
 
Fig. 2.   Effects of alpha 2AR-acting drugs on PTZ-induced seizure susceptibility. Shown are latencies to first MJ and C/T seizure. A, water (Dbh +/-, n = 13; Dbh -/-, n = 14) or clonidine (0.1 mg/kg: Dbh +/-, n = 14; Dbh -/-, n = 14) was administered 30 min prior to PTZ (40 mg/kg for Dbh +/-, 30 mg/kg for Dbh -/-). *P < 0.05 compared with water control. B, water (Dbh +/-, n = 12; Dbh -/-, n = 8) or yohimbine (10 mg/kg: Dbh +/-, n = 12; Dbh -/-, n = 8) was administered 30 min prior to PTZ (50 mg/kg for Dbh +/-, 40 mg/kg for Dbh -/-).

Activation of Central alpha 1ARs Inhibits PTZ-Induced Seizures in Dbh -/- Mice. While clonidine is a fairly selective alpha 2AR agonist, it has some activity at alpha 1ARs at high doses (Wu et al., 1987). We considered the possibility that our results with clonidine were due to concurrent activation of alpha 1ARs, but rejected this hypothesis based on the results of two experiments. First, decreasing the dose of clonidine to 1 µg/kg failed to reveal an anticonvulsant effect (data not shown). This dose was chosen because it is maximally effective at inhibiting PTZ-induced seizures in normal rats and electrically induced seizures in rats with 6-hydroxydopamine lesions of their noradrenergic systems (Dalton et al., 1985). Second, cirazoline (0.2 mg/kg), a selective alpha 1AR agonist, significantly increased latencies to MJ and C/T seizures in Dbh -/- mice (Fig. 3A). While eight of nine vehicle-treated Dbh -/- mice progressed to a C/T seizure at this dose of PTZ, only 2 of 10 cirazoline-treated Dbh -/- mice had seizures of this severity. Similar effects were obtained with 0.1 and 0.5 mg/kg cirazoline (data not shown). This anticonvulsant effect was blocked by pretreatment with prazosin (1 mg/kg), a selective alpha 1AR antagonist, further verifying the importance of alpha 1ARs (Fig. 3B). While cirazoline did not have a significant anticonvulsant effect on Dbh +/- controls (Fig. 3A), prazosin alone (1 mg/kg) had a proconvulsant effect (Fig. 3C), reducing latencies to MJ and C/T seizures. These data suggest that the inhibition of seizures by endogenous NE in normal animals involves alpha 1ARs.


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 3.   Effects of alpha 1AR-acting drugs on PTZ-induced seizure susceptibility. Shown are latencies to first MJ and C/T seizure. A, water (n = 8 for each genotype) or cirazoline (0.2 mg/kg: Dbh +/-, n = 8; Dbh -/-, n = 9) was administered 30 min prior to PTZ (50 mg/kg for Dbh +/-, 40 mg/kg for Dbh -/-). *P < 0.05 compared with water control; **P < 0.01 compared with water control. B, vehicle (1.5% DMSO, 1.5% Cremaphor EL in water) or prazosin (1 mg/kg) was administered 30 min prior to water or cirazoline (0.2 mg/kg; n = 10 for each drug treatment group), which was administered to Dbh -/- mice 30 min prior to PTZ (40 mg/kg). *P < 0.05 compared with water control. ***P < 0.001 compared with water control. dagger P < 0.01 compared with cirazoline alone. C, vehicle (1.5% DMSO, 1.5% Cremaphor EL in water) or prazosin (1 mg/kg; n = 12 for each drug treatment group) was administered to Dbh +/- mice 30 min prior to PTZ (40 mg/kg). *P < 0.05 compared with vehicle control; **P < 0.01 compared with vehicle control. D, water (n = 6) or phenylephrine (3 mg/kg; n = 7) was administered to Dbh -/- mice 30 min prior to PTZ (40 mg/kg).

Because alpha 1AR agonists have profound effects on the peripheral nervous system, we determined whether the anticonvulsant effect of cirazoline was mediated by central or peripheral alpha 1 receptors. In contrast to cirazoline, phenylephrine (3 mg/kg), an alpha 1AR agonist that cannot cross the blood-brain barrier, failed to inhibit seizures in Dbh -/- mice (Fig. 3D) despite having qualitatively similar effects on ptosis and piloerection (data not shown). These results suggest that Dbh -/- mice are more susceptible to PTZ-induced seizures at least in part because of a lack of central alpha 1AR signaling.

beta 2AR Signaling Inhibits PTZ-Induced Seizures. To investigate the contribution of beta AR signaling to the anticonvulsant effect of NE, we treated mice with isoproterenol, a nonselective beta AR agonist. We found that isoproterenol (10 mg/kg) increased latencies to PTZ-induced seizures in both Dbh -/- and Dbh +/- mice (Fig. 4A). To determine which beta AR subtype was responsible for the anticonvulsant effect of isoproterenol, mice were treated with a preferential beta 1AR (dobutamine) or a preferential beta 2AR (albuterol) agonist prior to PTZ administration. While dobutamine (10 mg/kg) did not significantly affect seizure susceptibility in Dbh -/- mice, albuterol (10 mg/kg) prolonged the latency to both MJ and C/T seizures (Fig. 4B). Nearly all water-treated Dbh -/- mice (22 of 23) progressed to C/T seizures, while only 6 of 22 albuterol-treated Dbh -/- mice had seizures of that severity (data from Fig. 4, B and C, combined). Albuterol also significantly protected Dbh +/- control mice (Fig. 4B). Propanolol (10 mg/kg), a nonselective beta AR antagonist, blocked the anticonvulsant effect of albuterol in terms of latency to MJ but not C/T seizure in Dbh -/- mice (Fig. 4C). To determine whether the inability of propanolol to completely block the anticonvulsant effect of albuterol was due to blockade of beta 1ARs as well as beta 2ARs, we tested the beta 2AR-selective antagonist ICI-118,551. ICI-118,551 (10 mg/kg) abolished the anticonvulsant effect of albuterol on MJ, but only partially blocked its effect on C/T seizures (Fig. 4C). Nadolol (10 mg/kg), a nonselective beta AR antagonist that cannot cross the blood-brain barrier, had effects similar to ICI-118,551 (Fig. 4C). Last, neither propanolol (10, 20, or 40 mg/kg) nor ICI-118,551 affected susceptibility to PTZ-induced seizures in Dbh +/- control mice (Fig. 4D; data not shown). These results suggest that beta 2ARs do not mediate the anticonvulsant effect of endogenous NE, but that exogenous activation of beta 2ARs can inhibit PTZ-induced seizures in mice.


View larger version (40K):
[in this window]
[in a new window]
 
Fig. 4.   Effects of beta AR-acting drugs on PTZ-induced seizure susceptibility. Shown are latencies to first MJ and C/T seizure. A, water (Dbh +/-, n = 10; Dbh -/-, n = 9) or isoproterenol (10 mg/kg: Dbh +/-, n = 10; Dbh -/-, n = 9) was administered 30 min prior to PTZ (50 mg/kg for Dbh +/-, 40 mg/kg for Dbh -/-). *P < 0.05 compared with water control. **P < 0.01 compared with water control. ****P < 0.0001 compared with water control. B, water (Dbh +/-, n = 9; Dbh -/-, n = 13), albuterol (10 mg/kg: Dbh +/-, n = 9; Dbh -/-, n = 5), or dobutamine (10 mg/kg: Dbh -/-, n = 8) was administered 30 min prior to PTZ (50 mg/kg for Dbh +/-, 40 mg/kg for Dbh -/-). **P < 0.01 compared with water control. ***P < 0.001 compared with water control. C, water, propanolol (10 mg/kg), ICI-118,551 (10 mg/kg), or nadolol (10 mg/kg) was administered 30 min prior to water or albuterol (10 mg/kg), which was administered to Dbh -/- mice (water + water, n = 18; water + albuterol, n = 17; propanolol + albuterol, n = 9; ICI-118,551 + albuterol, n = 12; nadolol + albuterol, n = 16) 30 min prior to PTZ (40 mg/kg). *P < 0.05 compared with water control. **P < 0.01 compared with water control. ***P < 0.001 compared with water control. dagger P < 0.05 compared with albuterol alone. dagger dagger P < 0.01 compared with albuterol alone. D, water, propanolol (10 mg/kg), or ICI-118,551 (10 mg/kg) was administered to Dbh +/- mice (n = 10 for each drug treatment group) 30 min prior to PTZ (40 mg/kg).

    Discussion
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
Conclusions
References

The results of this study are summarized in Table 1 and reveal three important points. First, stimulation of alpha 2ARs has a proconvulsant effect on PTZ-induced seizures. This effect is probably mediated by the inhibition of NE release via presynaptic alpha 2 autoreceptors, because the proconvulsant effect is abolished in Dbh -/- mice. Second, stimulation of either alpha 1ARs or beta 2 ARs restores normal PTZ-induced seizure susceptibility upon Dbh -/- mice. Third, alpha 1AR but not beta 2AR antagonists confer increased seizure susceptibility upon control mice, suggesting that endogenous NE inhibits seizures by activating alpha 1ARs in animals with normal NE content.


                              
View this table:
[in this window]
[in a new window]
 
TABLE 1
Summary of AR agonist and antagonist effects on PTZ-induced seizure susceptibility

Dbh -/- mice are more susceptible to PTZ-induced seizures than Dbh +/- controls, and some AR agonists and antagonists affect susceptibility differently in the two genotypes. up-arrow  represents an increase in latency, down-arrow  represents a decrease in latency, and - represents no change in latency to PTZ-induced seizure compared with the no drug control for each genotype.

Role of alpha 2ARs in PTZ Seizures. The literature indicates that alpha 2ARs are the most likely receptor type to mediate the anticonvulsant effect of endogenous NE to PTZ-induced seizures in rats. Multiple independent investigators have found that alpha 2AR agonists inhibit PTZ-induced seizures (Papanicolaou et al., 1982; Scotti de Carolis et al., 1986; Löscher and Czuczwar, 1987), and that alpha 2AR antagonists block the anticonvulsant effect of alpha 2AR agonists and potentiate PTZ-induced seizures on their own (Lazarova and Samanin, 1983; Scotti de Carolis et al., 1986). Because endogenous NE is anticonvulsant, the interpretation of these results was that the anticonvulsant effect of alpha 2AR agonists was mediated by postsynaptic receptors. However, one of the earliest publications on this theme reported a proconvulsant effect of clonidine on PTZ-induced seizures in mice, and proposed that activation of presynaptic alpha 2ARs decreased NE release and exacerbated seizures (Oishi et al., 1979). Since then, both proconvulsant (Fletcher and Forster, 1988) and anticonvulsant (Löscher and Czuczwar, 1987; Amabeoku et al., 1994) effects of clonidine in mice have been reported. We undertook this study using Dbh -/- mice that lack endogenous NE to determine whether clonidine is pro- or anticonvulsant and whether these effects are mediated by pre- or postsynaptic alpha 2ARs. We found that clonidine has a proconvulsant effect on control mice but no effect on Dbh -/- mice, suggesting that in our paradigm clonidine decreases NE release via presynaptic alpha 2ARs in normal animals.

Clonidine has been shown to have an anticonvulsant effect in models where seizures were induced by kainic acid (Baran et al., 1985), amygdala kindling (Gellman et al., 1987; Löscher and Czuczwar, 1987), and air blast stimulation (Löscher and Czuczwar, 1987). However, clonidine has exhibited proconvulsant effects in others, such as electroconvulsions (Löscher and Czuczwar, 1987), quinolinic acid (Wu et al., 1987), and spontaneous petit mal seizures (Micheletti et al., 1987). In fact, clonidine has a proconvulsant effect in humans with intractable focal epilepsies (Kirchberger et al., 1998). One explanation for these conflicting results is that these diverse seizure-inducing paradigms involve distinct mechanisms and different brain regions, and therefore the effect of alpha 2AR agonists and antagonists varies with alpha 2AR distribution and function, species, and strain. Because endogenous NE is anticonvulsant in most seizure-inducing paradigms, we hypothesize that the proconvulsant effects seen with clonidine are mediated by alpha 2AR autoreceptors, while the anticonvulsant effects observed are mediated by alpha 2AR heteroreceptors on target neurons.

Role of alpha 1ARs in PTZ Seizures. There are three results that support our conclusion that alpha 1AR activation mediates the anticonvulsant effects of endogenous NE in PTZ-induced seizures. First, Dbh -/- mice that lack endogenous NE are hypersensitive to PTZ-induced seizures, and administration of an alpha 1AR-selective agonist can restore normal sensitivity. Second, inhibition of PTZ-induced seizures by cirazoline can be blocked by prazosin, a selective alpha 1AR antagonist. Third, prazosin administration in control mice results in increased PTZ sensitivity. The inability of cirazoline to significantly protect Dbh +/- mice may mean that alpha 1ARs are already maximally activated in normal animals during seizures. Although alpha 1ARs have not previously been implicated in PTZ-induced seizures (Löscher and Czuczwar, 1987), alpha 1 agonists have anticonvulsant activity in many other seizure models, including amygdala kindling (Löscher and Czuczwar, 1987), air blast stimulation (Löscher and Czuczwar, 1987), focal cortical penicillin (Neuman, 1986), audiogenic seizures (Yan et al., 1998), quinolinic acid (Wu et al., 1987), and spontaneous petit mal seizures (Micheletti et al., 1987). Further evidence that alpha 1ARs mediate the anticonvulsant effect of endogenous NE in some situations comes from studies showing changes in alpha 1AR density in seizure-sensitive rats (Nicoletti et al., 1986; Gundlach et al., 1995), mice (Jazrawi and Horton, 1986), and humans with epilepsy (Brière et al., 1986).

Role of beta 2ARs in PTZ Seizures. Our results indicate that activation of beta 2ARs, but not beta 1ARs, inhibits PTZ-induced seizures in both norepinephrine-deficient Dbh -/- mice and Dbh +/- mice, which have normal NE content. Because mice lacking NE were affected, we conclude that albuterol exerts its anticonvulsant action via postsynaptic beta 2ARs and does not involve an increase in NE release via presynaptic beta 2ARs. The lack of a proconvulsant effect of the beta AR antagonists propanolol or ICI-118,551 on Dbh +/- mice suggests that beta 2ARs do not mediate the anticonvulsant effect of endogenous NE, even though beta 2AR agonists can have an anticonvulsant affect on mice with normal NE content. In fact, it is unclear whether endogenously released NE typically activates beta 2ARs in the brain. For example, beta 2ARs have a much lower affinity than beta 1ARs for NE (for review, see Molinoff, 1984). beta 1AR but not beta 2AR antagonists affect behavior (Pandey et al., 1995) and only beta 1ARs undergo changes in response to treatments that chronically alter synaptic NE (Minneman et al., 1982). However, exogenously supplied beta 2AR agonists affect behavior, beta 2AR density (O'Donnell, 1990), and NE release (Murugaiah and O'Donnell, 1995), suggesting that beta 2ARs are functional when artificially stimulated, as they appear to be in our study.

The anticonvulsant site of action of albuterol remains unresolved. While all of the beta 2AR antagonists exhibited the ability to reverse the effect of albuterol on latency to MJ, none were especially efficacious at blocking its effects on generalized C/T seizures. The fact that isoproterenol and nadolol, which are reported not to cross the blood-brain barrier, had any effect suggests that albuterol is acting at least partially via a peripheral mechanism. Because NE has profound effects on the cardiovascular system, it is possible that these drugs are exerting their effects on seizures by modulating heart rate or blood pressure. However, an alternative explanation is that these drugs may get into the brain when administered peripherally at high doses. For example, i.p. administration of 1 mg/kg isoproterenol results in a substantial increase in phosphorylation of Ca2+ channels in the central nervous system (J. Hell, personal communication). Comparison of the anticonvulsant effects of central versus peripheral albuterol administration will help resolve this issue. The inability of any beta AR antagonist to completely block the anticonvulsant effect of albuterol may be related to relative doses, receptor affinities, and blood-brain barrier permeability.

    Conclusions
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
Conclusions
References

This study comprehensively examines the anticonvulsant pharmacology of NE for a single convulsant agent, PTZ. The use of Dbh -/- mice, which lack NE, circumvents many of the caveats in the interpretation of results obtained in the presence of endogenous NE, and provides an example of how a combination of genetics and pharmacology can be a powerful approach in the study of neurotransmitter function.

It is important to note that each class of convulsant agent probably elicits seizures by distinct mechanisms that most likely involve different regions of the brain. Therefore, it is not surprising that there is not one "universal" noradrenergic receptor that mediates the anticonvulsant effect of NE for all seizure models. Because Dbh -/- mice are also more susceptible to seizures induced by kainic acid, flurothyl, and sound (Szot et al., 1999), it will be possible to apply the same approach to the identification of the anticonvulsant NE receptor(s) involved in other seizure models.

    Acknowledgments

We thank Sumitomo Pharmaceuticals for the generous donation of L-threo-3,4-dihydroxyphenylserine (DOPS) and D. Kim, R. Gillis, and M. Szczypka for critical reading of this manuscript.

    Footnotes

Accepted for publication May 25, 2001.

Received for publication April 5, 2001.

D.W. and N.S.M. were supported by the Howard Hughes Medical Institute. P.S. was supported by the National Alliance for Research on Schizophrenia and Depression and the Department of Veterans Affairs.

Address correspondence to: Dr. David Weinshenker, Howard Hughes Medical Institute, Box 357370, University of Washington, Seattle, WA 98195. E-mail: dzw{at}genetics.washington.edu

    Abbreviations

NE, norepinephrine; AR, adrenoreceptor; PTZ, pentylenetetrazole; Dbh, dopamine beta -hydroxylase; MJ, myoclonic jerk; C/T, clonic/tonic; DMSO, dimethyl sulfoxide.

    References
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
Conclusions
References


0022-3565/01/2983-1042-1048$03.00
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weinshenker, D.
Right arrow Articles by Palmiter, R. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weinshenker, D.
Right arrow Articles by Palmiter, R. D.


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition